Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NeuroPace (NPCE) EBITDA (2020 - 2025)

Historic EBITDA for NeuroPace (NPCE) over the last 6 years, with Q3 2025 value amounting to -$2.6 million.

  • NeuroPace's EBITDA rose 3872.26% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.2 million, marking a year-over-year increase of 3220.74%. This contributed to the annual value of -$21.7 million for FY2024, which is 3424.26% up from last year.
  • According to the latest figures from Q3 2025, NeuroPace's EBITDA is -$2.6 million, which was up 3872.26% from -$6.8 million recorded in Q2 2025.
  • NeuroPace's 5-year EBITDA high stood at -$2.6 million for Q3 2025, and its period low was -$13.2 million during Q2 2022.
  • For the 5-year period, NeuroPace's EBITDA averaged around -$8.2 million, with its median value being -$8.5 million (2021).
  • Per our database at Business Quant, NeuroPace's EBITDA plummeted by 13981.68% in 2021 and then skyrocketed by 4322.34% in 2023.
  • NeuroPace's EBITDA (Quarter) stood at -$11.0 million in 2021, then grew by 0.71% to -$10.9 million in 2022, then surged by 43.22% to -$6.2 million in 2023, then soared by 41.08% to -$3.7 million in 2024, then rose by 28.83% to -$2.6 million in 2025.
  • Its EBITDA stands at -$2.6 million for Q3 2025, versus -$6.8 million for Q2 2025 and -$5.1 million for Q1 2025.